Stock MIRM MIRUM PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Real-time Estimate Cboe BZX
Other stock markets
 03:17:09 2024-05-03 pm EDT 		5-day change 1st Jan Change
25.9 USD +1.19% Intraday chart for Mirum Pharmaceuticals, Inc. +5.68% -12.43%
Apr. 17 Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target MT
Apr. 02 Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
BU
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals LIVMARLI Receives Positive Reimbursement Recommendation by Canada s CADTH for Patients with Cholestatic Pruritusin Alagille Syndrome
AQ
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
BU
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
BU
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
BU
Mirum Pharmaceuticals - Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI
AQ
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
BU
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
BU
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
BU
Mirum Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
BU
Mirum Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) Jan 11, 2024
AQ
Mirum Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
BU
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRM Stock
  4. News Mirum Pharmaceuticals, Inc.
  5. Press Releases